| Title |
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
|
|---|---|
| Published in |
Clinical Cancer Research, May 2020
|
| DOI | 10.1158/1078-0432.ccr-19-2299 |
| Pubmed ID | |
| Authors |
Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Berris van Kessel, Martijn W. Heymans, Lisa C. Holthof, Christie P.M. Verkleij, Rengasamy Boominathan, Bhavesh Vaidya, Jocelyn Sendecki, Amy Axel, Francois Gaudet, Kodandaram Pillarisetti, Sonja Zweegman, Homer C. Adams, Tuna Mutis, Niels W.C.J. van de Donk |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 27% |
| Japan | 1 | 9% |
| Germany | 1 | 9% |
| France | 1 | 9% |
| Unknown | 5 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 19% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 6 | 11% |
| Other | 4 | 7% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 7 | 12% |
| Unknown | 19 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 25% |
| Biochemistry, Genetics and Molecular Biology | 12 | 21% |
| Immunology and Microbiology | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 4% |
| Unspecified | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 18 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 539. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#46,442
of 25,738,558 outputs
Outputs from Clinical Cancer Research
#8
of 13,302 outputs
Outputs of similar age
#1,959
of 411,359 outputs
Outputs of similar age from Clinical Cancer Research
#1
of 183 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,302 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 411,359 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 183 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.